Eli Lilly And's Revenue in the fiscal year 2025 $ 65,179.00 millions
Eli Lilly And's Revenue in the fiscal year 2024 $ 45,042.70 millions
Eli Lilly And's Revenue in the fiscal year 2023 $ 34,124.10 millions
Eli Lilly And's Revenue in the fiscal year 2022 $ 28,541.40 millions
Eli Lilly And's Revenue in the fiscal year 2021 $ 28,318.40 millions
LLY Revenue second quarter 2026 Y/Y Growth Comment
Eli Lilly And Company achieved in the second quarter 2026, above Company average Revenue rise of 47.67% year on year, to $ 22,974.00 millions.
Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 58 other companies have achieved higher Revenue growth. While Eli Lilly And Company' s Revenue jump of 47.67% ranks overall at the positon no. 482 in the second quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Eli Lilly And's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
29.6 %
2.51 %
-19.38 %
LLY's II. Quarter Q/Q Revenue Comment
Eli Lilly And Company achieved in the II. Quarter 2026 above company average sequential Revenue jump of 16.04%, to $ 22,974.00 millions, from $19,799.00 millions in the first quarter.
Within Major Pharmaceutical Preparations industry 51 other companies have achieved higher Revenue quarter on quarter growth. While Eli Lilly And's Revenue growth quarter on quarter, overall rank is 611.
Eli Lilly And Company achieved in the II. Quarter 2026 above company average sequential Revenue jump of 16.04%, to $ 22,974.00 millions, from $19,799.00 millions in the first quarter.
Within Major Pharmaceutical Preparations industry 51 other companies have achieved higher Revenue quarter on quarter growth. While Eli Lilly And's Revenue growth quarter on quarter, overall rank is 611.
Eli Lilly And's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 30 2026)
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending
$ 79,665.80
$ 72,249.50
$ 65,179.00
$ 59,419.80
$ 53,258.10
Y / Y Revenue Growth (TTM)
49.58 %
47.44 %
44.7 %
45.41 %
36.83 %
Year on Year Revenue Growth Overall
Ranking
# 460
# 430
# 385
# 451
# 336
Seqeuential Revenue Change (TTM)
10.26 %
10.85 %
9.69 %
11.57 %
8.68 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 1666
# 1638
# 1186
# 1672
# 1222
Cumulative Revenue growth Comment
With 49.58% annual Revenue growth, Eli Lilly And Company would report a record annual Revenue growth if the fiscal year would end on Jun 30 2026.
In the Healthcare sector 110 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 430 to 460.
With 49.58% annual Revenue growth, Eli Lilly And Company would report a record annual Revenue growth if the fiscal year would end on Jun 30 2026.
In the Healthcare sector 110 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 430 to 460.
About Eli Lilly And Revenue Growth Rates (LLY), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
82.08%